PinPointe FootLaser for the Treatment of Onychomycosis
This study has been completed.
Sponsor:
PathoLase, Inc.
Information provided by:
PathoLase, Inc.
ClinicalTrials.gov Identifier:
NCT00935649
First received: July 7, 2009
Last updated: April 8, 2013
Last verified: November 2010
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
To evaluate the safety and efficacy of the PathoLase FootLaser treatment of infected toenails.
| Condition | Intervention | Phase |
|---|---|---|
|
Infected Toenails Onychomycosis |
Device: PinPointe FootLaser |
Phase 2 Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Multi-Center Trial: Evaluation of PinPointe FootLaser Treatment for Infected Toenails (Onychomycosis) |
Further study details as provided by PathoLase, Inc.:
Primary Outcome Measures:
- Nail Bed Clearing [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]Change in amount of clear nail over time.
Secondary Outcome Measures:
- Mycology [ Time Frame: 48 weeks ] [ Designated as safety issue: No ]KOH, PCR and cultures of patients who were bilaterally positive or negative for each test.
| Enrollment: | 134 |
| Study Start Date: | June 2009 |
| Study Completion Date: | November 2010 |
| Primary Completion Date: | November 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Randomized great toe
Subjects with both great toes infected. Right/left randomized to treatment / no treatment
|
Device: PinPointe FootLaser
Medical laser
Other Name: PinPointe FootLaser
|
| No Intervention: Untreated Toe |
Detailed Description:
The study is a multi-center controlled study evaluating laser treatments of infected great toes in a randomized blinded study of approximately 125 subjects. Right and left great toes are randomized to treatment or no treatment. Samples from infected areas are sampled and evaluated for presence of fungus with KOH, PCR and culture tests. Nail bed clearing and nail plate growth are measured from high resolution photographs by a blinded evaluator. Subjects will be evaluated at baseline and at 8, 16, 24 and 48 weeks for safety and effectiveness of study treatment.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Volunteers of either sex,
- 18-80 years of age,
- Both great toes with clinical signs of infection.
- Positive KOH or culture test
Exclusion Criteria:
- Existing or history of cancer/skin malignancy,
- Use of oral antifungal agents in past 6 months,
- Use of topical antifungal agents in past 1 month,
- Loss of protective sensation in either foot,
- Infection involving lunula of either great toe,
- Longitudinal streaks/spikes of either great toenail,
- Distal nail thickness > 2 mm of either great toe,
- Prior surgical treatment of either great toe in past 12 months,
- Participation in another medical device/pharmaceutical study,
- Condition that investigator determines makes it unsafe for subject to participate,
- Pregnancy, breastfeeding or plans to become pregnant.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00935649
Locations
| United States, New York | |
| Rochester Laser Center | |
| Rochester, New York, United States, 14617 | |
| United States, Texas | |
| Endeavor Clinical Trials, PA | |
| San Antonio, Texas, United States, 78229 | |
| United States, Washington | |
| Dermatology Associates | |
| Seattle, Washington, United States, 98101 | |
| Canada, Ontario | |
| Mediprobe Research Inc | |
| London, Ontario, Canada, N5X 2P1 | |
Sponsors and Collaborators
PathoLase, Inc.
Investigators
| Study Director: | David M Harris, PhD | PathoLase, Inc. |
| Principal Investigator: | Bernard Goffe, MD | Dermatology Associates |
More Information
No publications provided
| Responsible Party: | David M Harris, PhD, PathoLase, Inc |
| ClinicalTrials.gov Identifier: | NCT00935649 History of Changes |
| Other Study ID Numbers: | CLN0001.p.A |
| Study First Received: | July 7, 2009 |
| Results First Received: | April 8, 2013 |
| Last Updated: | April 8, 2013 |
| Health Authority: | United States: Institutional Review Board Canada: Health Canada |
Keywords provided by PathoLase, Inc.:
|
Toenail Fungus PinPointe FootLaser Onychomycosis Fungal nails |
Additional relevant MeSH terms:
|
Onychomycosis Tinea Dermatomycoses Skin Diseases, Infectious |
Infection Mycoses Nail Diseases Skin Diseases |
ClinicalTrials.gov processed this record on May 23, 2013